Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.05 USD
-0.04 (-3.67%)
Updated May 24, 2024 03:59 PM ET
After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 1 - 20 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q23 Results; Data From Three Phase 3 Pivotal Studies Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FY23 Preliminary Revenues Disappoint, But Focus Should be on New Indications in the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2023 Weekend Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Updated Overall Survival Data For Xpovio in TP53 Wild-Type Endometrial Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Results; Xpovio Sales Slightly Above Our Expectations; Investor Focus Should Be on Ongoing Phase 3 Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Clinical Trial Agreement With BMY For Mezigdomide in Combination With Xpovio and Dexamethasone in r/r MM Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Results; Key Data Readouts Expected in 2024 and 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
As XPOVIO Demand Grows, Revenue Remains Flat
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Updated Data From SIENDO Study Subgroup Analysis of Xpovio in TP53 WT Endometrial Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
A While to Wait for SIENDO to Help Selinexor''s Sluggish Sales
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Xpovio Receives Fast Track Designation From the FDA for the Treatment of Myelofibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Initiation of Phase 3 Study of Xpovio and Jakafi in JAKi-Naive Patients With MF
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Solid Tumors - Week Ended May 26.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 26.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D